As of 2026-10-05, the Fair Value of Innate Pharma SA (IPH.PA) is -2.62 EUR. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 1.32 EUR, the upside of Innate Pharma SA is -298.94%.
With the market price of 1.32 EUR and our fair value calculation, Innate Pharma SA (IPH.PA) is not a good investment. Investing in IPH.PA stocks now will result in a potential loss of 298.94%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | 5Y Avg | |
| Net income | -52.81 | -58.10 | -7.57 | -49.47 | -49.18 | -43.43 |
| YoY growth | 17.47% | -10.02% | 86.97% | -553.51% | 0.59% | -91.70% |
| Market Cap (mil) | 123.60 |
| P/E | |
| Forward P/E |
| EPS | -0.52 |
| Avg earnings growth rate | -91.70% |
| TTM earnings | -49.18 |